Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Armodafinil Extension Study for Excessive Sleepiness
NCT00228553Phase 3Completed
- Sponsor
- Cephalon, Inc.
- Start
- May 2004
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, open-label, single-arm trial of armodafinil in narcolepsy, obstructive sleep apnea syndrome (OSAS) and shift work sleep disorder (SWSD), sponsored by Cephalon, Inc. Primary endpoint: Safety and Tolerability in This Patient Population Over Time. Started May 2004; status: completed.
02
Drugs
armodafinil
03
Conditions
narcolepsyobstructive sleep apnea syndrome (OSAS)shift work sleep disorder (SWSD)
Beyond the preview
Go deeper on NCT00228553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00228553.